optalert, Author at Optalert

About optalert

This author has not yet filled in any details.
So far optalert has created 78 blog entries.

Could blinks be the answer to Alzheimer’s disease?

September is World Alzheimer’s month, the international campaign which raises awareness and challenges the stigma that surrounds dementia. Around the world 50 million people have dementia, and each year there are nearly 10 million new cases. The total number of people with dementia is projected to reach 82 million by 2030! With over 100 forms of dementia, the most well-known form is Alzheimer’s disease (AD), which accounts for 50-60% of all cases. Although a widespread condition, diagnosis and treatment of AD today is inadequate. Often multiple tests including patient history, [...]

By optalert|2019-09-03T16:23:57+11:00September 3rd, 2019|Neurology, Pharmaceutical|

Press Release – Optalert awarded Australian Government – Automotive Innovation Lab Access Grant

Latest News Today, Melbourne based Medtech company, Optalert Australia, were announced as the recipient of the Australian Government - Automotive Innovation Lab Access Grant (AILAG). The grant will be used to advance the development of the Optalert Video Automotive technology solution for the objective, early prediction of drowsiness and attentiveness monitoring. The project aims to become a unique automotive innovation for Australia, with potential to lead to both local and international partnerships within the automotive industry. A timely project with the EU parliament also recently backing new measures to improve [...]

By optalert|2019-06-17T12:43:00+11:00June 17th, 2019|Automotive|

Supporting Industry 4.0 initiatives

Connecting the physical world with the digital world Industry 4.0 fundamentally changes the way in which businesses create and capture value. This shift is enabled by a set of technologies including autonomous robots, simulation technology, system integration, the Internet of Things (IoT), cybersecurity, cloud computing, additive manufacturing, augmented reality and big data. Industry 4.0 technologies have been around for a while individually, but more recently, they have begun to influence and impact each other. Enabled by the internet and a desire to significantly reduce costs, businesses can now take advantage [...]

By optalert|2019-04-29T14:26:57+11:00April 29th, 2019|Automotive, Goods & Passenger Transport, Mining|

Optalert in World first in fatigue research study

Press Release from the National Transport Commission: The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) today released the results of a world-first study into heavy vehicle driver fatigue. The two-year scientific study evaluated alertness monitoring technology and the impacts of work shifts on driver alertness. It analysed shift start time, the number of consecutive shifts, shift length, shift rotation, rest breaks and their likely impact on driver drowsiness and fatigue. Spokesperson and Theme Leader for the Alertness CRC Associate Professor [...]

By optalert|2019-04-16T11:01:22+11:00April 16th, 2019|Automotive|

BIO2019 Philadelphia – It Starts with One!

BIO International Convention is back in Philadelphia, June 3-6, to celebrate the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Optalert look forward to joining the global biotech community during partnering sessions and will be available for meetings through the official Bio2019 partnering portal, opening 2nd April 2019. Optalert will present their latest scientific technology for the objective measurement of drowsiness, which is also being used in pharmaceutical drug trials and neurological research studies in the fields of Epilepsy, Traumatic Brain [...]

By optalert|2019-03-29T16:35:34+11:00March 29th, 2019|Pharmaceutical|

Las Vegas CES2019 Highlights

The Consumer Electronics Show (CES2019) dazzled participants once again with glimpses of technologies and products on the horizon for the future. With over 180,000 attendees from 150 different countries, circulating over 11 venues throughout Las Vegas. Optalert’s key conversations at this year’s event included autonomous vehicles, enhanced ‘early warning’ drowsiness and distraction features, and AI assisting in remote healthcare technology. Optalert’s Chief Technical Officer Simon Block, shares some of his top highlights for the show: 1. Automotive Innovation Intelligent cars dominated the conversation in the automotive market, with seamless connectivity critical [...]

By optalert|2019-01-17T14:05:06+11:00January 17th, 2019|Automotive, Pharmaceutical|

Keep your holidays happy by being vigilant on the roads this year.

The holiday season is the time of the year when impaired and drowsy driving accidents are most prevalent. Many of us would never imagine that a holiday celebration could result in a fatality or imprisonment. The risks associated with driving while drowsy are very real. Driving performance can be impaired, reaction times increase and it could result in tragic consequences for everyone involved. The Drowsy Driving Problem Drowsy driving usually happens when a driver has not slept enough, but it can also happen due to drinking alcohol, untreated sleep disorders, [...]

By optalert|2018-12-20T10:51:32+11:00December 20th, 2018|Automotive|

Introducing the BlinQ system by Optalert

Optalert is pleased to introduce the BlinQ system for the measurement of drowsiness or wakefulness in clinical trials. Optalert uses advanced patented algorithms to determine the exact drowsiness or wakefulness of a subject. By applying Artificial Intelligence techniques and machine learning Optalert has been able to objectively quantify drowsiness or wakefulness. Utilising the Johns Drowsiness Scale (JDS), Optalert's future-proofed approach can advance clinical drug trial timelines and deliver new therapies to market faster. Current methodologies for measuring drowsiness or wakefulness are used across a wide range of clinical drug trials including anti-depressants, shift-work disorder, narcolepsy [...]

By optalert|2018-12-17T15:50:16+11:00December 17th, 2018|Pharmaceutical|

Challenges of pharmaceutical companies

Pharmaceutical companies face many challenges, with hundreds of new drugs required to transition through clinical trial phases, regulatory processes and to market, more quickly and more efficiently. The Centre for the Study of Drug Development (CSDD) estimates the cost of developing a prescription drug that gains market approval at $2.6 billion. Even more remarkable is that 90% of medicines that start being tested in people don’t reach the market because they are unsafe or ineffective. “May cause drowsiness” This is a common warning label on [...]

By optalert|2018-11-08T10:52:12+11:00November 2nd, 2018|Pharmaceutical|

5 of the greatest technological discoveries in the medical field

Every technological discovery aims to improve our health, safety, and quality of life. Every day, we marvel over exciting new developments that emerge from each corner of the globe. A few weeks ago, we looked at seven of the most significant pharmacological discoveries, and this week, we want to expand our exploration into great technology that help diagnose or treat disease and improve health. As we find ourselves increasingly immersed in advanced digital technology, we’re introduced to new discoveries that sound almost as if they came straight out of a [...]

By optalert|2018-10-11T13:08:24+11:00October 10th, 2018|Pharmaceutical|

12 Next